The clinical setback for the AMPLIFY-7P study, involving 144 patients with pancreatic cancer, arrived just days after B. Riley Securities maintained a bullish $27 price target on the stock. By the close of trading on June 15, the share price had plummeted to $4.08, leaving stakeholders to reconcile the discrepancy between recent analyst optimism and the company's internal data. The firm SueWallSt has launched an investigation into whether Elicio Therapeutics provided misleading information to the market regarding the viability of its primary pipeline candidate. Potential claimants are being urged to compile brokerage records as attorneys evaluate whether the company’s disclosures adequately prepared investors for the high-stakes clinical outcome.
Elicio Therapeutics Faces Legal Scrutiny Following Phase 2 Trial Failure
Investors in Elicio Therapeutics saw their holdings crater by 72.5% in a single session after the company announced its lead clinical candidate, ELI-002 7P, failed to meet primary endpoints in a Phase 2 trial. The sudden collapse followed a dismal Q1 earnings report that revealed zero revenue and mounting losses.
Comments (0)
No comments yet. Be the first!